A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future

Leslie Citrome1, Joseph P McEvoy2, Mark S Todtenkopf3, David McDonnell4, Peter J Weiden3 1Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA; 2Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University, Augusta, GA, USA; 3A...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Citrome L, McEvoy JP, Todtenkopf MS, McDonnell D, Weiden PJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	antipsychotic efficacy metabolic dysregulation weight gain Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/6c66697a7c8948df816d2bd7dae97e15
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6c66697a7c8948df816d2bd7dae97e15
record_format	dspace
spelling	oai:doaj.org-article:6c66697a7c8948df816d2bd7dae97e152021-12-02T05:39:38ZA commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future1178-2021https://doaj.org/article/6c66697a7c8948df816d2bd7dae97e152019-09-01T00:00:00Zhttps://www.dovepress.com/a-commentary-on-the-efficacy-of-olanzapine-for-the-treatment-of-schizo-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Leslie Citrome1, Joseph P McEvoy2, Mark S Todtenkopf3, David McDonnell4, Peter J Weiden3 1Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA; 2Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University, Augusta, GA, USA; 3Alkermes, Inc., Waltham, MA, USA; 4Alkermes Pharma Ireland Ltd., Dublin, IrelandCorrespondence: Leslie Citrome 11 Medical Park Drive, Suite 106, Pomona, NY 10970, USATel +1 845 362 2081Email citrome@cnsconsultant.comAbstract: Olanzapine is a second-generation atypical antipsychotic with proven efficacy for the treatment of schizophrenia. Approved in 1996, olanzapine is one of the most studied antipsychotics, resulting in a considerable amount of clinical data across diverse patient populations. Despite the fact that olanzapine is associated with a known risk of metabolic side effects, including weight gain, many clinicians continue to prescribe olanzapine for the treatment of schizophrenia with the expectation of additional therapeutic antipsychotic efficacy relative to other first-line atypical antipsychotics. The goal of this narrative is to revisit the role of oral olanzapine in the management of patients with schizophrenia, including those with recently diagnosed schizophrenia (“first-episode”), those with an established schizophrenia diagnosis who experience acute exacerbations, those receiving long-term antipsychotic treatment as a maintenance intervention, and those with suboptimal response to antipsychotic treatment, including treatment resistance. Collectively, data from published literature support the favorable efficacy of olanzapine compared with other first- and second-generation antipsychotics, including lower rates of treatment discontinuation and clinically meaningful improvements in the symptoms of schizophrenia. The development of antipsychotic medications with the favorable efficacy of olanzapine, but with reduced weight gain, could address a major unmet need in the treatment of schizophrenia.Keywords: antipsychotic, efficacy, metabolic dysregulation, weight gainCitrome LMcEvoy JPTodtenkopf MSMcDonnell DWeiden PJDove Medical Pressarticleantipsychoticefficacymetabolic dysregulationweight gainNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 2559-2569 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	antipsychotic efficacy metabolic dysregulation weight gain Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	antipsychotic efficacy metabolic dysregulation weight gain Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Citrome L McEvoy JP Todtenkopf MS McDonnell D Weiden PJ A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
description	Leslie Citrome1, Joseph P McEvoy2, Mark S Todtenkopf3, David McDonnell4, Peter J Weiden3 1Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA; 2Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University, Augusta, GA, USA; 3Alkermes, Inc., Waltham, MA, USA; 4Alkermes Pharma Ireland Ltd., Dublin, IrelandCorrespondence: Leslie Citrome 11 Medical Park Drive, Suite 106, Pomona, NY 10970, USATel +1 845 362 2081Email citrome@cnsconsultant.comAbstract: Olanzapine is a second-generation atypical antipsychotic with proven efficacy for the treatment of schizophrenia. Approved in 1996, olanzapine is one of the most studied antipsychotics, resulting in a considerable amount of clinical data across diverse patient populations. Despite the fact that olanzapine is associated with a known risk of metabolic side effects, including weight gain, many clinicians continue to prescribe olanzapine for the treatment of schizophrenia with the expectation of additional therapeutic antipsychotic efficacy relative to other first-line atypical antipsychotics. The goal of this narrative is to revisit the role of oral olanzapine in the management of patients with schizophrenia, including those with recently diagnosed schizophrenia (“first-episode”), those with an established schizophrenia diagnosis who experience acute exacerbations, those receiving long-term antipsychotic treatment as a maintenance intervention, and those with suboptimal response to antipsychotic treatment, including treatment resistance. Collectively, data from published literature support the favorable efficacy of olanzapine compared with other first- and second-generation antipsychotics, including lower rates of treatment discontinuation and clinically meaningful improvements in the symptoms of schizophrenia. The development of antipsychotic medications with the favorable efficacy of olanzapine, but with reduced weight gain, could address a major unmet need in the treatment of schizophrenia.Keywords: antipsychotic, efficacy, metabolic dysregulation, weight gain
format	article
author	Citrome L McEvoy JP Todtenkopf MS McDonnell D Weiden PJ
author_facet	Citrome L McEvoy JP Todtenkopf MS McDonnell D Weiden PJ
author_sort	Citrome L
title	A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
title_short	A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
title_full	A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
title_fullStr	A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
title_full_unstemmed	A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
title_sort	commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/6c66697a7c8948df816d2bd7dae97e15
work_keys_str_mv	AT citromel acommentaryontheefficacyofolanzapineforthetreatmentofschizophreniathepastpresentandfuture AT mcevoyjp acommentaryontheefficacyofolanzapineforthetreatmentofschizophreniathepastpresentandfuture AT todtenkopfms acommentaryontheefficacyofolanzapineforthetreatmentofschizophreniathepastpresentandfuture AT mcdonnelld acommentaryontheefficacyofolanzapineforthetreatmentofschizophreniathepastpresentandfuture AT weidenpj acommentaryontheefficacyofolanzapineforthetreatmentofschizophreniathepastpresentandfuture AT citromel commentaryontheefficacyofolanzapineforthetreatmentofschizophreniathepastpresentandfuture AT mcevoyjp commentaryontheefficacyofolanzapineforthetreatmentofschizophreniathepastpresentandfuture AT todtenkopfms commentaryontheefficacyofolanzapineforthetreatmentofschizophreniathepastpresentandfuture AT mcdonnelld commentaryontheefficacyofolanzapineforthetreatmentofschizophreniathepastpresentandfuture AT weidenpj commentaryontheefficacyofolanzapineforthetreatmentofschizophreniathepastpresentandfuture
_version_	1718400301695762432

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future

Ejemplares similares